New grant opportunity on Grants.gov: Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaska Natives

Funding Opportunity ID: 308248 Opportunity Number: RFA-IP-19-001 Opportunity Title: Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaska Natives Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Cooperative Agreement Category of Funding Activity: Health Category Explanation: CFDA Number(s): 93.185 Eligible Applicants: State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Additional Information on Eligibility: Additional Information on Eligibility: For-profit institutions are not eligible to apply. Agency Code: HHS-CDC-HHSCDCERA Agency Name: Department of Health and Human Services Centers for Disease Control and Prevention - ERA Posted Date: Oct 29, 2018 Close Date: Feb 01, 2019 Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date. Last Updated Date: Oct 29, 2018 Award Ceiling: $1,000,000 Award Floor: $750,000 Estimated Total Program Funding: $5,000,000 Expected Number of Awards: 1 Description: Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory tract infection including bronchiolitis and pneumonia in infants and children worldwide. The annual rate of RSV hospitalizations for children less than 2 years of age in the US is 5.2 per 1,000, but substantially higher among Native Americans. There are currently approximately 40 vaccines or antibody products in development designed to prevent RSV infections. With potential licensure of these products on the horizon, it will be important to establish baseline estimates of the burden of RSV infections in high-risk populations, like Native Americans, and to maintain surveillance post-licensure in order to evaluate impact. Native Americans are also at higher risk for severe respiratory infections associated with human metapneumovirus (HMPV) and other viruses, which will also be monitored through this system. Version: 1

Published at: October 30, 2018 at 03:15AM
View on Grants.gov